Reclassification of early stage breast cancer into treatment groups by combining the use of immunohistochemistry and microarray analysis
Fiche du document
1 avril 2019
- handle: 10670/1.2jsqud
Citer ce document
Kathleen A. Grant et al., « Reclassification of early stage breast cancer into treatment groups by combining the use of immunohistochemistry and microarray analysis », South African Journal of Science, ID : 10670/1.2jsqud
Métriques
Partage / Export
Résumé
Immunohistochemistry (IHC) is routinely used to approximate breast cancer intrinsic subtypes, which were initially discovered by microarray analysis. However, IHC assessment of oestrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor-2 (HER2) status, is a poor surrogate of molecular subtype. Therefore, MammaPrint/BluePrint (MP/BP) microarray gene expression profiling is increasingly used to stratify breast cancer patients into different treatment groups. In this study, ER/PR status, as reported by standard IHC and single-gene mRNA analysis using TargetPrint, was compared with molecular subtyping to evaluate the combined use of MP/BP in South African breast cancer patients. Pathological information of 74 ER/PR positive, HER2 negative tumours from 73 patients who underwent microarray testing, were extracted from a central breast cancer genomics database. The IHC level was standardised by multiplying the intensity score (0-3) by the reported proportion of positively stained nuclei, giving a score of 0-300. Comparison between mRNA levels and IHC determination of ER/PR status demonstrated a significant correlation (p